RT Journal Article
SR Electronic
T1 SARS-CoV-2 in first trimester pregnancy – does it affect the fetus?
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2020.06.08.20125195
DO 10.1101/2020.06.08.20125195
A1 Cour Freiesleben, Nina la
A1 Egerup, Pia
A1 Römmelmayer Hviid, Kathrine Vauvert
A1 Severinsen, Elin Rosenbek
A1 Kolte, Astrid Marie
A1 Westergaard, David
A1 Olsen, Line Fich
A1 Prætorius, Lisbeth
A1 Zedeler, Anne
A1 Christiansen, Ann-Marie Hellerung
A1 Nielsen, Josefine Reinhardt
A1 Bang, Didi
A1 Berntsen, Sine
A1 Ollé-López, Joaquim
A1 Ingham, Andreas
A1 Bello-Rodríguez, Judith
A1 Storm, Ditte Marie
A1 Ethelberg-Findsen, Jeppe
A1 Hoffmann, Eva R
A1 Wilken-Jensen, Charlotte
A1 Jørgensen, Finn Stener
A1 Westh, Henrik
A1 Løvendahl Jørgensen, Henrik
A1 Nielsen, Henriette Svarre
YR 2020
UL http://medrxiv.org/content/early/2020/06/09/2020.06.08.20125195.abstract
AB Background Several viral infections are known to be harmful to the fetus in the first trimester of pregnancy and can cause increased nuchal translucency thickness and pregnancy loss. Currently, no evidence exists regarding possible effects of SARS-CoV-2 in first trimester pregnancies.Methods Cohort 1 included pregnant women with a double test taken between Feb. 17 and Apr. 23, 2020, during the SARS-CoV-2 epidemic peak in Denmark. The double test was taken as part of the first trimester risk assessment. Cohort 2 included women with a first trimester pregnancy loss before double test. Serum from the double test or from a blood sample, in case of pregnancy loss, was analyzed for SARS-CoV-2 antibodies. The results were correlated to the nuchal translucency thickness and the number of pregnancy losses.Results In total, 1,019 pregnant women with double test and 36 women with pregnancy loss participated in the study. Thirty (2.9%) women had SARS-CoV-2 antibodies in the serum from the double test. All women with pregnancy loss prior to the double test were negative for SARS-CoV-2 antibodies. There were no significant differences in nuchal translucency thickness for women testing positive (n=14) versus negative (p=0.20) or grey zone (n=16) versus negative (p=0.28). In total, 54 women experienced a pregnancy loss of whom two had grey zone or positive SARS-CoV-2 antibodies.Conclusion Maternal SARS-CoV-2 infection did not seem harmful in first trimester pregnancies. Infection had no effect on the nuchal translucency thickness and women with SARS-CoV-2 antibodies were not overrepresented among women with pregnancy loss.Competing Interest StatementThe authors have declared no competing interest.Funding StatementHSN and colleagues received a grant from the Danish Government for research of Covid-19 among pregnant women. AI, JOL, JBR, DMS, JEF, and ERH received funding from a Novo Nordisk Foundation (NNF) Young Investigator Grant (NNF15OC0016662) and a Danish National Science Foundation Center Grant (6110-00344B). AI received a Novo Scholarship. JOL is funded by an NNF Pregraduate Fellowship (NNF19OC0058982). DW is funded by the NNF (NNF18SA0034956, NNF14CC0001, NNF17OC0027594). AMK is funded by a grant from the Rigshospitalets research fund.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The study was approved by Knowledge Centre on Data Protection Compliance, The Capital Region of Denmark (P-2020-255) and by the Scientific Ethics Committee of the Capital Region of Denmark (journal number H-20022647). All participants in the study provided written informed consentAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data referred to in the manuscript are included in the approved database for this study